Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by MetLife Investment Management LLC

MetLife Investment Management LLC grew its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 7.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 145,265 shares of the biopharmaceutical company's stock after buying an additional 10,538 shares during the period. MetLife Investment Management LLC owned 0.11% of Halozyme Therapeutics worth $6,945,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in HALO. Venturi Wealth Management LLC acquired a new position in shares of Halozyme Therapeutics in the 4th quarter valued at $69,000. Retirement Systems of Alabama lifted its position in Halozyme Therapeutics by 23.5% in the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company's stock valued at $22,282,000 after acquiring an additional 74,173 shares during the last quarter. Shaker Investments LLC OH boosted its stake in Halozyme Therapeutics by 12.3% in the fourth quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company's stock valued at $3,601,000 after acquiring an additional 8,249 shares in the last quarter. Foster & Motley Inc. grew its holdings in shares of Halozyme Therapeutics by 118.6% during the fourth quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company's stock worth $1,113,000 after purchasing an additional 12,630 shares during the last quarter. Finally, Jennison Associates LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth about $731,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Wall Street Analyst Weigh In

HALO has been the topic of a number of research reports. Wells Fargo & Company dropped their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Benchmark reissued a "buy" rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Piper Sandler upped their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. JPMorgan Chase & Co. boosted their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Finally, HC Wainwright reiterated a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a research report on Friday. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $62.89.

Halozyme Therapeutics Stock Down 0.3 %

Shares of NASDAQ:HALO traded down $0.16 during midday trading on Monday, hitting $60.33. 253,760 shares of the company's stock traded hands, compared to its average volume of 1,437,978. The firm's fifty day moving average price is $60.50 and its two-hundred day moving average price is $55.14. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. Halozyme Therapeutics, Inc. has a twelve month low of $37.97 and a twelve month high of $66.00. The company has a market cap of $7.45 billion, a PE ratio of 17.59, a P/E/G ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to analysts' expectations of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. On average, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Michael J. Labarre sold 1,697 shares of the company's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares of the company's stock, valued at $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jeffrey William Henderson sold 503 shares of the stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total transaction of $32,217.15. Following the transaction, the director now owns 33,108 shares in the company, valued at $2,120,567.40. This trade represents a 1.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 22,200 shares of company stock worth $1,286,568 in the last 90 days. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.